Genmab’s Total Number of Voting Rights and Total Share

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genmab’s Total Number of Voting Rights and Total Share Capital

Company Announcement

  • Publication of voting rights and share capital 

Copenhagen, Denmark; November 28, 2014 – Genmab A/S (OMX: GEN) announces that p ursuant to section 6 of Executive Order no. 1442 of December 13, 2013 on Issuers' Disclosure Obligations, the total nominal value of Genmab A/S' share capital is DKK 56 ,967,419 at the end of November 2014, which is made up of 56 ,967,419 shares of a nominal value of DKK 1 each, corresponding to 56 ,967,419 votes.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in late stage clinical development for multiple myeloma. Additionally Genmab has a clinical pipeline with both late and early stage programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody™ platform which creates effector function enhanced antibodies. Genmab's deep antibody expertise is expected to provide a stream of future product candidates.  Partnering of selected innovative product candidates and technologies is a key focus of Genmab’s strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com . 

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo™; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody™ and UniBody ® . Arzerra ® is a registered trademark of the GSK group of companies. 

Company Announcement no. 57
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Racura's AML Trial Clears Its First Crucial Hurdle

Updated Category News Views 95

One signature from Sheba does not cure leukemia, but it does move Racura Oncology from talking about EMILI to doing the hard, expensive work of enrolling patients. For a company at this stage, that distinction matters. Ethics approval for the seamless Phase 2b/3 RC220 study in relapsed or refractory acute myeloid leukemia is a real operational milestone, not the sort of...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 86

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 102

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 93

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 121

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
RazorMetrics' Fast 500 Run Merits a Harder Investor Look

Updated Category News Views 75

A 4,488% growth figure can make even a seasoned skeptic sit upright. RazorMetrics landed at No. 20 on Deloitte's 2026 Technology Fast 500 after ranking No. 12 in 2025, and it again took the top Texas slot. That is serious momentum for an Austin company working on one of healthcare's most stubborn expenses: prescription drugs. Still, this is healthcare cost containment,...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 111

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 72

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 139

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Cytonics Refines CYT-108 Trial Plan With Decade OA Data

Updated Category News Views 119

A Better Map Is Not a Working Drug Knee osteoarthritis has chewed up plenty of promising development plans because the disease moves at an aggravatingly uneven crawl. Cytonics has done something sensible before pushing deeper into CYT-108: it went back to long-term untreated patient data and asked which knees actually deteriorate fast enough for a trial to detect...

Continue Reading

Top 5 Most Recently Viewed Articles

Ollie's Bargain Outlet Raises Over $1.3 Million for Charity

Updated Category News Views 216

Ollie's Bargain Outlet Makes a Difference this Holiday Season Ollie's Bargain Outlet recently announced an impressive fundraising effort, raising over $1.3 million for the Marine Toys for Tots Program. This initiative highlights the company's commitment to giving back to the community during the holiday season. From early November to early December, participating Ollie's...

Continue Reading
Navigating the Integer Holdings Corporation Class Action Concerns

Updated Category News Views 147

Your Rights as an Investor in Integer Holdings Corporation If you've invested in Integer Holdings Corporation (NYSE: ITGR), you might be feeling concerned about recent developments. The company, known for its role in cardiac rhythm management and cardiovascular product manufacturing, is currently under scrutiny due to allegations that it misled investors regarding the...

Continue Reading
Indochino Welcomes Sean Wrenn as New Vice President of Retail

Updated Category News Views 163

Indochino Welcomes Sean Wrenn as New Vice President of Retail INDOCHINO, the leader in made to measure apparel, has appointed Sean Wrenn as the new Vice President of Retail Sales and Operations. With over two decades of retail experience, Sean is set to enhance the company’s operations and customer engagement. Sean Wrenn's Background and Expertise Sean Wrenn joins...

Continue Reading
Innovative Partnership Enhances Efficiency in Dairy Processing

Updated Category News Views 200

Collaboration to Boost Dairy Processing Efficiency In an exciting development within the dairy processing sector, CADDi, a renowned provider of digital solutions for manufacturers, has teamed up with Dairy Conveyor Corporation (DCC Automation). This collaboration marks a significant step towards optimizing supply chains and fostering better communication across DCC's...

Continue Reading
Celebrating Food and Beverage Excellence in the Middle East

Updated Category News Views 171

Celebrating Excellence in Food and Beverage The Middle East Food & Beverage Excellence Awards is an annual event that brings together the best in the industry, turning the spotlight on the remarkable achievements of food and beverage professionals. Last night, at the stunning JW Marriott Marina, industry leaders in the Middle East gathered for an unforgettable evening...

Continue Reading